Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

GUPPY's (5127 JP): Medley (4480 JP) Tender Offer at JPY3,250

Medley (4480 JP): 2023 Started on Strong Note; Full-Year Guidance Reaffirmed; Mid-Term Plan Revised

Medley (4480) To Buy Out Guppy's (5127) At ¥3,250 (9.4x Aug26 EV/FCF)

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/medley-inc" target="_blank" data-smartkarma-citation="entities:31041:1" rel="noopener">Medley (4480 JP)</a> reported better-than-expected 2023 result. Revenue increased 45% YoY to ¥20.5B, EBITDA jumped 77% YoY to ¥3.4B, and net profit increased 152% YoY to ¥2.6B.</li>
<li>The company expects 2024 revenue of ¥27.1B (up 32% YoY) and EBITDA of ¥3.9B (up 15% YoY). However, net profit is expected to remain flat at ¥2.6B in 2024.</li>
<li>Medley has established new mid-term targets. The company aims to achieve an EBITDA of ¥20B on revenue of ¥100B in 2029, representing 5-year revenue CAGR of 30%.</li>
</ul>



Medley (4480 JP) reported better-than-expected 2023 result. Revenue increased 45% YoY to ¥20.5B, EBITDA jumped 77% YoY to ¥3.4B, and net profit increased 152% YoY to ¥2.6B.
The company expects 2024 revenue of ¥27.1B (up 32% YoY) and EBITDA of ¥3.9B (up 15% YoY). However, net profit is expected to remain flat at ¥2.6B in 2024.
Medley has established new mid-term targets. The company aims to achieve an EBITDA of ¥20B on revenue of ¥100B in 2029, representing 5-year revenue CAGR of 30%.


Medley (4480 JP): 2023 Result Beats Guidance; Sees Flat Profit on Double-Digit Sales Growth in 2024